News stories about Cellect Biotechnology (NASDAQ:APOP) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cellect Biotechnology earned a news impact score of 0.17 on Accern’s scale. Accern also gave news articles about the company an impact score of 43.6370387667751 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Cellect Biotechnology (NASDAQ APOP) opened at 6.638 on Thursday. The company’s 50-day moving average price is $7.84 and its 200-day moving average price is $7.42. Cellect Biotechnology has a 52-week low of $2.30 and a 52-week high of $13.50. The stock’s market cap is $35.71 million.

Separately, ValuEngine upgraded Cellect Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-cellect-biotechnology-nasdaqapop-share-price/1467382.html.

About Cellect Biotechnology

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Receive News & Ratings for Cellect Biotechnology Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.